Biotech Acquisition Company Warrant
BIOTW
BIOTW was delisted on the 2nd of February, 2023.
34 hedge funds and large institutions have $6.34M invested in Biotech Acquisition Company Warrant in 2021 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 3 closing their positions.
467% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 3
205% more capital invested
Capital invested by funds: $2.08M → $6.34M (+$4.26M)
70% more funds holding
Funds holding: 20 → 34 (+14)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Ramius Advisors
New York
|
+$349K |
| 2 |
LA
Linden Advisors
New York
|
+$236K |
| 3 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$173K |
| 4 |
DCM
DG Capital Management
New York
|
+$156K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$156K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCP
Corbin Capital Partners
New York
|
-$108K |
| 2 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$90K |
| 3 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$62.5K |
| 4 |
WA
Whitebox Advisors
Minneapolis,
Minnesota
|
-$43.4K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$41.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $26K | +$21K | +30,229 | New |
|
|
AA
27
AQR Arbitrage
Greenwich,
Connecticut
| $23K | +$18.4K | +26,499 | New |
|
|
PCM
28
Prelude Capital Management
New York
| $14K | +$11.1K | +16,004 | New |
|
|
EAM
29
Exos Asset Management
New York
| $11K | – | – | – |
|
|
30
Bank of America
Charlotte,
North Carolina
| $9K | -$41.7K | -60,008 | -86% |
|
|
BCM
31
Basso Capital Management
Stamford,
Connecticut
| $9K | – | – | – |
|
|
AA
32
Ancora Advisors
Cleveland,
Ohio
| $4K | +$3.51K | +5,050 | New |
|
|
BFM
33
Boothbay Fund Management
New York
| $1K | +$9.56K | +13,761 | New |
|
|
MI
34
MMCAP International
Grand Cayman,
Cayman Islands
| $258 | – | – | – |
|
|
MP
35
Mangrove Partners
Greenwich,
Connecticut
| – | -$90K | -150,000 | Closed |
|
|
WA
36
Whitebox Advisors
Minneapolis,
Minnesota
| – | -$43.4K | -62,500 | Closed |
|
37
Goldman Sachs
New York
| – | -$7K | -11,240 | Closed |
|
BIOTW Hedge Fund Activity: Q2 2021 in Review
34 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Warrant (BIOTW) for Q2 2021, worth a combined $6.34M — up 205% from $2.08M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new BIOTW positions and 3 closed out — a net gain of 14 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Ramius Advisors, opening a new position worth an estimated $349K. The largest seller was Corbin Capital Partners, cutting an estimated $108K.
- 34 institutional investors held Biotech Acquisition Company Warrant (BIOTW) as of Q2 2021, up from 20 in Q1 2021.
- Funds reported $6.34M of Biotech Acquisition Company Warrant stock for Q2 2021, up 205% quarter-over-quarter.
- 17 funds opened new Biotech Acquisition Company Warrant positions in Q2 2021 and 3 closed out, a net change of +14 holders.
- The largest Biotech Acquisition Company Warrant buyer in Q2 2021 was Ramius Advisors, an estimated $349K added.
- The largest Biotech Acquisition Company Warrant seller in Q2 2021 was Corbin Capital Partners, an estimated $108K sold.
Based on aggregated 13F filings for Q2 2021.